港股异动 | 亚盛医药-B(06855)涨超5% 耐立克治疗SDH缺陷型GIST患者的III期研究获CDE临床许可

智通财经06-13

智通财经APP获悉，亚盛医药-B(06855)涨超5%，截至发稿，涨5.48%，报20.4港元，成交额1302.81万港元。消息面上，亚盛医药近日宣布，公司原创1类新药奥雷巴替尼（商品名：耐立克®；研发代号：HQP1351）获国家药监局药物审评中心临床试验许可，将开展其针对系统性全身治疗失败的琥珀酸脱氢酶（SDH）缺陷型胃肠间质瘤（GIST）患者的全球注册III期临床研究。这是亚盛医药在实体瘤领域...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2443054437?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-13 10:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2443054437","market":"us","top_or_hot":-1,"title":"港股异动 | 亚盛医药-B(06855)涨超5% 耐立克治疗SDH缺陷型GIST患者的III期研究获CDE临床许可","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，亚盛医药-B(06855)涨超5%，截至发稿，涨5.48%，报20.4港元，成交额1302.81万港元。消息面上，亚盛医药近日宣布，公司原创1类新药奥雷巴替尼（商品名：耐立克®；研发代号：HQP1351）获国家药监局药物审评中心临床试验许可，将开展其针对系统性全身治疗失败的琥珀酸脱氢酶（SDH）缺陷型胃肠间质瘤（GIST）患者的全球注册III期临床研究。这是亚盛医药在实体瘤领域...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1134603.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 亚盛医药-B(06855)涨超5% 耐立克治疗SDH缺陷型GIST患者的III期研究获CDE临床许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 亚盛医药-B(06855)涨超5% 耐立克治疗SDH缺陷型GIST患者的III期研究获CDE临床许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 10:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1134603.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，亚盛医药-B(06855)涨超5%，截至发稿，涨5.48%，报20.4港元，成交额1302.81万港元。消息面上，亚盛医药近日宣布，公司原创1类新药奥雷巴替尼（商品名：耐立克®；研发代号：HQP1351）获国家药监局药物审评中心临床试验许可，将开展其针对系统性全身治疗失败的琥珀酸脱氢酶（SDH）缺陷型胃肠间质瘤（GIST）患者的全球注册III期临床研究。这是亚盛医药在实体瘤领域...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1134603.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCEI","symbol_name":"国企指数","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1134603.html","article_id":"2443054437","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443054437","pubTimestamp":1718246770,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，亚盛医药近日宣布，公司原创1类新药奥雷巴替尼获国家药监局药物审评中心临床试验许可，将开展其针对系统性全身治疗失败的琥珀酸脱氢酶缺陷型胃肠间质瘤患者的全球注册III期临床研究。这是亚盛医药在实体瘤领域临床开发的重大里程碑。西南证券指，新适应症的获批大幅扩大了患者适用人群，为耐药患者带来新的治疗选择，有望进一步提升耐立克的商业化表现。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","HSCEI":"国企指数","BK4134":"信息科技咨询与其它服务","07226":"XL二南方恒科","06855":"亚盛医药-B","09939":"开拓药业-B","BK1574":"生物医药B类股","BK1515":"抗疫概念","BK4017":"黄金","HSTECH":"恒生科技指数","YANG":"三倍做空富时中国ETF-Direxion","BK1161":"生物科技","CDE":"科尔黛伦矿业","III":"信息服务"},"translate_title":"Hong Kong stocks changed, Ascentage Pharma-B (06855) rose more than 5%, and the phase III study of Nerik in the treatment of SDH-deficient GIST patients was approved by CDE clinical approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"06855":1,"07226":1,"09939":1,"CDE":1,"HSCEI":1,"HSTECH":1,"III":1,"YANG":1},"content_text":"智通财经APP获悉，亚盛医药-B(06855)涨超5%，截至发稿，涨5.48%，报20.4港元，成交额1302.81万港元。消息面上，亚盛医药近日宣布，公司原创1类新药奥雷巴替尼（商品名：耐立克®；研发代号：HQP1351）获国家药监局药物审评中心临床试验许可，将开展其针对系统性全身治疗失败的琥珀酸脱氢酶（SDH）缺陷型胃肠间质瘤（GIST）患者的全球注册III期临床研究。这是亚盛医药在实体瘤领域临床开发的重大里程碑。耐立克®是中国首个上市的第三代BCR-ABL抑制剂，目前已有两项适应症获批，分别为治疗任何TKI耐药、并伴有T315I突变的慢性髓细胞白血病（CML）慢性期（-CP）和加速期（-AP）的成年患者；和治疗对一代和二代TKI耐药和/或不耐受的CML-CP成年患者。西南证券指，新适应症的获批大幅扩大了患者适用人群，为耐药患者带来新的治疗选择，有望进一步提升耐立克的商业化表现。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443054437"}